partnering

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

Astellas builds in protein degraders with PeptiDream deal

Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

News

Roche eyeing $7bn deal to buy Roivant drug; report

Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco

Astellas adds to cell therapy drive with Poseida deal

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Astellas builds in protein degraders with PeptiDream deal

Pieris wields axe after losing AZ as partner for elarekibep

Pfizer inks $7bn strategic level R&D deal with Flagship

Roche eyeing $7bn deal to buy Roivant drug; report

Telix to buy radiopharma rival ITM for $1.65bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks